Clinical development failure
The company’s value depends on positive data from Cantrixil and Paccal Vet studies.
- Scope
- Cantrixil and Paccal Vet
- Materiality
- high
Vivesto
Vivesto AB is a Swedish drug development company based in Stockholm that develops oncology programs for both human and veterinary use. Its portfolio centers on Cantrixil for blood cancer and Paccal Vet, a micellar paclitaxel program being studied in dogs and cats with cancer.
4
0.23
0.20
| % | |
|---|---|
| Human oncology programs | 50% Development-stage cancer therapies for difficult-to-treat human malignancies. |
| Veterinary oncology programs | 50% Cancer treatments and studies for dogs and cats with solid tumors and HSA. |
Vivesto does not sell to mass-market end customers; its commercial counterparties are primarily pharmaceutical and...
- Pharmaceutical licensing partnersprimary
Buy or license development-stage oncology assets such as Cantrixil for further clinical development and commercialization.
- Veterinary oncology partnersprimary
Potential partners for Paccal Vet who can advance animal cancer programs through later-stage development and market access.
- Clinical research sitessecondary
Hospitals and veterinary centers that conduct the company’s pilot, PK, tox, and dose-finding studies.
Vivesto is headquartered in Solna, Sweden and is listed on Nasdaq Stockholm. Its development work is international: the...
- •Headquartered in Solna, Sweden
- •Listed on Nasdaq Stockholm under ticker VIVE
- •Clinical work spans the United States, Europe, and Asia
- •Paccal Vet dog study runs at U.S. clinical centers
- •Global partnering network supports out-licensing efforts
Vivesto’s strategy is to advance its two oncology programs through the next value-inflection milestones and use data to...
01
Advance clinical development of Cantrixilshort-term
Human oncology data can create partnering interest and future licensing value.
02
Progress Paccal Vet studiesshort-term
Veterinary oncology data can broaden the partner universe and validate the platform.
03
Pursue partnering and licensingmedium-term
The business model depends on external partners to fund later-stage development and commercialization.
Vivesto is exposed to the typical risks of a development-stage biotech company: clinical failure, regulatory...
Financing risk
As a development-stage biotech with no product revenue, Vivesto depends on capital to fund operations.
- Scope
- Corporate funding runway
- Materiality
- high
Partnering/commercialization risk
The business model assumes later-stage development and commercialization will be done with partners.
- Scope
- Licensing and out-licensing execution
- Materiality
- high
Regulatory and study-design risk
Clinical and veterinary studies must satisfy regulators and generate usable data.
- Scope
- Human and veterinary oncology programs
- Materiality
- medium
Lease accounting under RFR 2
Affects balance sheet and expense timing
Related-party loan conversion and equity issuance
Affects financing cash flow, equity, and interest expense
Development-stage expense recognition
Drives reported operating loss and quarterly volatility
IFRS 18
IFRS 18 transition assessment
May change line-item presentation and comparability
: 11/08/2026